Introduction {#Sec1}
============

Over recent years, there has been an increasing interest in developing stem cell-based regenerative medicine therapies for patients with kidney disease. Stem cell therapies are already showing great promise in rodent models of acute and chronic kidney disease \[[@CR1]\], and several clinical trials are now underway to assess the safety and efficacy of these novel therapies in humans with kidney disease (see Table [1](#Tab1){ref-type="table"}). It should be noted, however, that while stem cell therapies could be useful for ameliorating acute or chronic renal injury, the consensus view is that they would be of little benefit in the context of end-stage renal disease (ESRD). The best treatment option for ESRD is kidney transplantation, but the shortage of donor kidneys means that most patients do not get offered a transplant, a situation which has stimulated efforts to develop 'bioengineered' kidneys. Whilst challenging, advances in biomaterials research and stem cell biology, including cellular reprogramming technologies, means that bioengineered kidneys for patients with ESRD could be possible in the future. For instance, in 2013, a bioengineered rat kidney was constructed by seeding rat neonatal kidney cells and human umbilical cord endothelial cells on a decellularised adult rat kidney scaffold \[[@CR2]••\]. Importantly, these synthetic kidneys showed some evidence of functionality and could produce 'rudimentary' urine in rat hosts \[[@CR2]••\]. For human patients, the ideal components of a bioengineered kidney would be autologous stem cells and non-immunogenic biomaterial scaffolds, thus avoiding immune rejection and/or life-long treatment with immunosuppressants. In this review, we will discuss current progress towards the development of bioengineered kidneys, with particular focus on the following key issues: (i) the optimal source of autologous stem cells, (ii) bioengineering strategies and (iii) safety aspects.Table 1Clinical trials using stem cell therapiesClinical trial nameClinical trial identifierPurposeStatusSponsorEstimated study completion datePilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal DiseaseNCT02176434This pilot study of combined kidney and hematopoietic stem cell transplantation attempts to establish a protocol to induce immunological tolerance as a new strategy to prevent renal graft rejection. If successful, this strategy would restore renal function, while avoiding the risks associated with long-term standard anti-rejection therapy, and would represent the first option to cure end-stage renal disease.RecruitingUniversity of ZurichAugust 2018Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney DiseaseNCT02166489This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).CompletedRoyan Institute, TehranJanuary 2016Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant PatientsNCT00183248This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without infusions of bone marrow stem cells from the kidney donor. The purpose of this study is to find out which strategy is more effective in preventing organ rejection and maintaining patient health.CompletedUniversity of MiamiNovember 2009Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal FailureNCT01152411To evaluate the safety and efficacy (to know / observe for Proof of concept in five Indian patients) if any, of autologous bone marrow derived stem cells injected into the Renal Artery in five (initially five patients, can be increased to ten patients after observing the initial results) patients with Chronic Renal FailureUnknownInternational Stem Cell Services LimitedUnknownInduction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx InfusionNCT00497926Use of a combination of an Enriched Hematopoetic Stem Cell Infusion and kidney transplantation from the same donor to try to avoid the need for long-term anti-rejection drug therapy. The desired result of this study is to allow the body to develop "tolerance" to the transplanted kidney.RecruitingUniversity of LouisvilleMarch 2030Effect of BM-MSCs in DCD Kidney TransplantationNCT02561767To determine the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells in kidney transplantation from Chinese donation after citizen's death (DCD).Not yet Opened for RecruitmentSun Yat-Sen UniversityOctober 2017Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionNCT00498160Induction of Donor Specific Tolerance in Recipients of Kidney Allografts by Donor Bone Marrow Cell Infusion (Deceased Donors) and Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionCurrentUniversity of LouisvilleDecember 2024Mesenchymal Stem Cells After Renal or Liver TransplantationNCT01429038To evaluate the safety and tolerability of MSC administration after liver or kidney transplantation.RecruitingUniversity Hospital of LiegeFebruary 2017Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) (RMCL-CL001)NCT02525263A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All enrolled subjects will be treated with up to two injections of NKA at least 6 months apart.Not yet Opened for RecruitmentRegenMed (Cayman) Ltd.January 2018Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney AllograftsNCT00658073To evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantationCompletedFuzhou General HospitalOctober 2010Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft NephropathyNCT00659620The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.CompletedFuzhou General HospitalMay 2010Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell TransplantationNCT02199301To evaluate the Tolerance induction in KT recipients with donor hematopoietic stem cell transplantation (HSCT).RecruitingSamsung Medical CenterDecember 2017MSC for Occlusive Disease of the KidneyNCT01840540To determine the safety and toxicity of intra-arterial infused autologous adipose derived mesenchymal stromal (stem) cells in patients with vascular occlusive disease of the kidney.OpenedMayo ClinicApril 2017Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)NCT02195323To provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).CompletedRoyan InstituteJanuary 2016Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive DrugsNCT00319657To determine if blood stem cells injected after kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn. Patients must have a healthy, completely human leukocyte antigen (HLA)-matched brother or sister as the organ and stem cell donor.RecruitingStanford UniversityJuly 2016Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers (CIS/MSC08)NCT01275612To test the feasibility and safety of systemic infusion of donor ex-vivo expanded Mesenchymal Stem Cells to repair the kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin.RecruitingMario Negri Institute for Pharmacological ResearchMarch 2017Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis (STEFOG)NCT02693366To analyze the safety, renal function, metabolic disorders and quality of life data in patients with focal segmental glomerulosclerosis treated with endovascular infusion of bone marrow derived mononuclear cells.RecruitingUniversidade Federal do Rio de JaneiroJune 2017Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.NCT02563366This study is designed to investigate whether allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) can promote function recovery in patients with poor early graft function after kidney transplantation from Chinese Donation after Citizen Death (DCD).Not yet Opened for RecruitmentSun Yat-Sen UniversityDecember 2017Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant ToleranceNCT00752479To define the safety and biological/mechanistic effect of the systemic intravenous infusion of syngeneic ex-vivo expanded MSCs in living-related kidney transplant recipients (one or two HLA haplotype mismatches) under basiliximab/low-dose RATG induction therapy and maintenance immunosuppressive drugs with the ultimate objective to test the feasibility of safely achieving graft tolerance in a subsequent efficacy pilot study.TerminatedMario Negri Institute for Pharmacological ResearchDecember 2013Safety and Efficacy of BMMNC in Patients With Chronic Renal FailureNCT01876017Single center trial to check the safety and efficacy of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs) for the patient with CRFRecruitingChaitanya Hospital, PuneDecember 2016Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal FailureNCT01453816An Open-label, Non-Randomised, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Renal Artery and Intravenously in Patients With Renal FailureUnknownAgeless Regenerative InstituteJune 2015Hypoxia and Inflammatory Injury in Human Renovascular HypertensionNCT02266394To determine if the MSC infusion prior to percutaneous transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney blood flow and restoration of kidney function, as well as to assess the relationship between MSC dose and measures of kidney function.RecruitingMayo ClinicMarch 2019To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant PatientsNCT02409940Aim To investigate effect of MSCs on immune cell repertoire in a donor specific mediated response.RecruitingPostgraduate Institute of Medical Education and ResearchDecember 2016Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft NephropathyNCT00659620Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney functionUnknownFuzhou General HospitalMay 2010Stem Cells and Kidney Disease -- Clinical Trials; Source: [www.ClinicalTrials.gov](http://www.clinicaltrials.gov/)

Sourcing Autologous Cells with Renal Differentiation Potential {#Sec2}
==============================================================

The kidney is one of the most complex organs in the human body, consisting of more than 26 different cell types \[[@CR3]\]. Many studies have analysed the potential of autologous cells for treating kidney disease, both in preclinical models and in the clinic. There has been particular focus on the use of cells that either have their origin in the kidney or on cells of non-renal origin that can nevertheless generate specialised renal cells and can be easily sourced from the patient. Here, we give a brief overview of the most well-studied autologous sources, which include kidney-derived cells (KCs), mesenchymal stromal/stem cells (MSCs), adipose-derived regenerative cells (ADRCs) and induced pluripotent stem cells (iPSCs).

Adult Kidney Cells {#Sec3}
==================

A number of different approaches have been followed to identify, isolate and characterise stem or progenitor cells from human kidney biopsies, typically by investigating clonogenicity, expression of stem cell markers, differentiation potential and ability to ameliorate kidney injury in vivo following administration into rodent disease models \[[@CR4]--[@CR10]\]. One of the key tools has been the chimeric embryonic kidney rudiment assay developed by Unbekandt and Davies and its modified versions \[[@CR11]--[@CR14]\]. With this in vitro approach, the potential of the stem/progenitor cells to undergo renal differentiation can be assessed by mixing the cells with dissociated embryonic mouse kidney cells, which are then re-aggregated to form a chimeric rudiment. Using this approach, our group was able to show that kidney-derived stem cells isolated from newborn mice have the potential to integrate into embryonic kidney rudiments and contribute to developing nephron structures and glomeruli \[[@CR15]\].

In human kidneys, NCAM, Tra-1-60 and CD133 have been identified as putative stem/progenitor cell markers \[[@CR16]--[@CR21]\]. In vitro characterisation assays suggested that CD133^+^ cells have a range of stem cell properties, including clonogenicity, self-renewal and the potential to differentiate along the renal, endothelial, adipogenic and osteogenic lineages \[[@CR18]--[@CR21]\]. Furthermore, administration of the cells into the tail vein of mice with rhabdomyolysis-induced acute tubular injury, or adriamycin-induced glomerular injury, resulted in amelioration of histological damage and improved function \[[@CR18], [@CR20], [@CR22], [@CR23]\]. In these studies, the authors provided evidence that some of the CD133^+^ KCs have the potential to integrate into the affected renal structures, contributing to their repair.

An advantage of autologous CD133^+^ KCs is that they are already committed to the renal lineage and would therefore be expected to differentiate into specialised renal cells quite readily. A major drawback, however, is that the number of healthy KCs that could be retrieved from a renal biopsy from a patient with ESRD would probably be too small to permit adequate expansion in vitro; this is because the CD133^+^ KCs change their phenotype and become senescent after ∼7 passages, thus limiting their expansion capacity \[[@CR18], [@CR24], [@CR25]\]. Furthermore, there is no evidence that CD133^+^ KCs can generate all of the 26 different cell types in the kidney, so it is unlikely that they could be used to generate a bioengineered kidney.

MSCs {#Sec4}
====

MSCs can contribute to the regeneration and repair of various organs. However, although it has been reported that MSCs can generate specialised renal cells \[[@CR26], [@CR27]\], more recent studies have shown that the regenerative effects of MSCs in various rodent kidney injury models are mediated by paracrine factors, including growth factors and extracellular vesicles \[[@CR28]--[@CR30], [@CR31]•, [@CR32]--[@CR34]\], which can modulate the immune system and suppress inflammation. For instance, a recent study has shown that following intravenous injection of MSCs into a rhabdomyolysis model of tubular injury, despite significant improvement in renal histology and function, most cells were located in the lungs or injured muscle, and none were present in the kidney \[[@CR31]•\]. Even following direct administration into the kidney via the renal artery, MSCs were only transiently located within the glomerular capillaries or interstitium and did not differentiate into renal cells \[[@CR32], [@CR35]--[@CR38]\]. Moreover, MSCs that did persist in the kidney appeared to differentiate into adipocytes within the glomeruli \[[@CR39]\] and had an adverse effect on renal health. Taken together, these studies show that the therapeutic effects of MSCs are mediated by paracrine or even endocrine factors, which probably improve renal health by modulating the immune system. Consequently, MSCs would be of little use in the development of a bioengineered kidney.

ADRCs {#Sec5}
=====

ADRCs have recently become of interest as regenerative medicine therapies, not only because of their accessibility, but also due to their efficacy in repairing tissue damage, including ischaemia-induced injuries \[[@CR40]--[@CR44]\]. Recently, Cytori have developed a method for processing ADRCs under good laboratory practice (GLP) compliance by dissociating the adipose tissue and enriching the ADRCs in a functionally closed system using proprietary reagents \[[@CR45], [@CR46]\]. However, similarly to MSCs, ADRCs appear to ameliorate injury by paracrine factors rather than by differentiating to replace damaged tissue \[[@CR40]\] and would be unable to generate the different types of renal cells required to make a bioengineered kidney.

Thus, although therapeutic efficacy has been demonstrated for KCs, MSCs and ADRCs in rodent kidney injury models, there is no evidence that these cells can permanently integrate into injured kidneys or differentiate in situ to replace all types of damaged cells renal cells. Of note, for ADRCs or MSCs, only a limited capacity to differentiate into epithelial cells in vitro has been reported \[[@CR47], [@CR48]\]. This was supported by our own work using the chimeric embryonic kidney rudiment assay, in which both human and murine MSCs demonstrated not only failure to integrate and contribute to the development of renal structures, but also negatively affected the formation of nephron structures \[[@CR49]\]. These observations indicate that while MSCs and ADRCs could be effective autologous therapies for acute or even early stage chronic kidney disease, they would have no place in renal bioengineering strategies to treat ESRD patients. Adult KCs appear to have at least some renal differentiation potential in vitro, albeit limited, but autologous sourcing would be problematic, especially for patients with ESRD where very little healthy renal tissue remains.

iPSCs {#Sec6}
=====

Several studies have previously shown that murine embryonic stem cell (ESC)-derived mesodermal cells can be directed to differentiate into a range of renal cell types. This was achieved using various techniques, including co-culture methods with embryonic spinal cord, the kidney rudiment assay, or after injection ex vivo or in vivo into newborn mouse kidneys \[[@CR13], [@CR50]--[@CR53]\]. Although encouraging, a major drawback with ESCs is that they are not autologous and would therefore induce an immune response if incorporated into a bioengineered kidney. However, the development by Yamanaka and colleagues of a strategy to reprogramme adult cells into ESC-like induced pluripotent stem cells (iPSCs) \[[@CR54]\] means that autologous pluripotent stem cells are now available for personalised cell therapies. The original cocktail of Yamanaka factors, which consisted of Oct3/4, Sox2, Klf4 and c-myc, has since been optimised to replace the two oncogenes, c-myc and Klf4 \[[@CR55]\], thus making the iPSCs less tumourigenic. Furthermore, the use of 'non-integrating' methods to introduce the reprogramming factors has circumvented the need for lenti- or retroviral vectors \[[@CR56]\], which pose safety issues due to the fact that they integrate into the genome and can induce oncogenic transformation \[[@CR57]\].

Over the last few years, a number of groups have been able to develop protocols to direct the differentiation of iPSCs to nephron progenitor cells (capable of generating cells of the nephron; also known as 'metanephric mesenchyme') and renal progenitor cells (RPCs) (capable of generating cells of the nephron, collecting tubules and interstitium). Seminal work in this field came from the Nishinakamura group, who, using information gleaned from the mouse embryo, designed a 3-stage differentiation protocol for directing the differentiation of ESCs or iPSCs to nephron progenitors \[[@CR58]••\]. This was achieved by incubating ESCs or iPSCs with various growth factors, including Activin, Bmp4, FGF9 and the Wnt agonist CHIR99021, at specific time points to mimic the temporal regulation of mesoderm differentiation in vivo. Apart from Nishinakamura, various other groups have described protocols for directing the differentiation of iPSCs into the renal lineage \[[@CR58]••, [@CR59]--[@CR62], [@CR63]••, [@CR64]••, [@CR65], [@CR66], [@CR67]•\], with recent studies by the Little and Bonventre groups showing that iPSC-derived RPCs can self-organise into kidney organoids containing glomerular and tubular structures with evidence of transport function and endothelial cell integration \[[@CR63]••, [@CR64]••, [@CR68]\]. These studies present an exciting breakthrough in the field because for the first time, they show that all cells of the kidney can be generated from an autologous cell source, potentially opening the door to the development of bioengineered kidneys (Fig. [1](#Fig1){ref-type="fig"}). In the next section, we will discuss three strategies whereby iPSC-derived RPCs could be used for this purpose.Fig. 1Schematic diagram showing 3 potential methods for making bioengineered kidneys using autologous cells. *1* iPSC-derived RPCs and endothelial cells self-organise in vitro to generate renal organoids. *2* iPSC-derived RPCs and endothelial cells are introduced into decellularised human or pig kidneys via the renal artery (endothelial cells) and ureter (RPCs). *3* iPSC-derived RPCs, endothelial cells and an appropriate matrix are printed according to a computer-generated organ 'blueprint'

Bioengineering Strategies {#Sec7}
=========================

Here, we will focus on the following three strategies that have potential for developing bioengineered kidneys in the future: (i) self-organisation of RPCs to generate renal organoids, (ii) seeding of RPCs into decellularised kidney scaffolds and (iii) 3D bioprinting of RPCs and synthetic matrices.

RPC-Derived Organoids {#Sec8}
=====================

Since the 1990s, various groups have explored the possibility of transplanting kidney rudiments derived from rodent, pig and human foetal kidneys into adult hosts. In most cases, the rudiments showed some evidence of growth and functionality, irrespective of whether they were transplanted under the kidney capsule \[[@CR69], [@CR70]\], into the kidney parenchyma \[[@CR71]\], near the abdominal aorta \[[@CR72]\] or into the omentum \[[@CR70], [@CR73], [@CR74]\]. However, there are several technical problems with rudiment transplantation that would prevent this approach from being used in the clinic. Firstly, the rudiments would be non-autologous and therefore immunogenic. Secondly, in these early studies, the rudiments did not connect to the host's ureter, leading in some cases to the development of hydronephrosis. Thirdly, although the rudiments grew in their new hosts, they did not mature beyond a neonatal stage and their filtering capacity was only equivalent to 2 % of that of an adult kidney \[[@CR72], [@CR75]\].

With the advancements in generating iPSC-derived RPCs, the first of these problems could now be overcome. As discussed above, under the appropriate culture conditions, iPSC-derived RPCs can give rise to both metanephric mesenchyme (the nephron progenitors) and ureteric bud (the progenitors of the collecting tubules and ureter) \[[@CR63]••, [@CR64]••\]. Remarkably, it was shown that these two primordial cell types could differentiate appropriately in vitro and self-organise to form 3D organoids comprising nephrons complete with glomeruli, proximal and distal tubules and loops of Henle, which were associated with ureteric bud-derived collecting tubules. These organoids also had iPSC-derived renal interstitial and endothelial cells \[[@CR64]••\].

However, the problems of connecting the organoids to the host's urine excretory system and of promoting their maturation so that they can function as adult kidneys are yet to be overcome. Some progress has been made towards connecting transplanted kidney rudiments to the host's ureter, with one study showing that the ureters of transplanted rat kidney rudiments can be anastomosed to the host's urinary system \[[@CR72]\], and more recently, the group of Yokoo has been able to connect pig kidney rudiment ureters with a bladder generated from a transplanted cloaca \[[@CR76]\]. Whilst impressive, these approaches would not be suitable for transplanted organoids as these RPC-derived structures lack a ureter (Fig. [1](#Fig1){ref-type="fig"}).

Decellularization of Kidney Scaffolds {#Sec9}
=====================================

Decellularization of animal or human organs in combination with re-cellularization using autologous progenitor and endothelial cells is the most promising approach to generating bioengineered organs ex vivo and seems to offer the quickest route to clinical applications \[[@CR77]--[@CR79]\]. During the decellularization process, the cellular compartment of a given organ is removed through delivery of a detergent-based solution via the innate vasculature throughout the organ parenchyma. This approach has been successfully used to generate a bioengineered airway consisting of a decellularised cadaveric trachea seeded with autologous MSC-derived chondrocytes and bronchial epithelial cells derived from a patient with bronchial stenosis. The airway was used to replace the stenosed bronchus and the patient had a very good outcome and, importantly, did not require immunosuppressant therapy \[[@CR80], [@CR81]\]. In the case of the kidney, a number of decellularization protocols have been established in rodent, pig, rhesus monkey and human kidneys \[[@CR2]••, [@CR82], [@CR83]•, [@CR84]--[@CR87]\]. These protocols involve the use of detergents or enzymes which are perfused in an antegrade fashion from the renal artery through the kidney vasculature (and sometimes through the ureter) \[[@CR83]•, [@CR85]\], thus removing all cells \[[@CR67]•, [@CR88], [@CR89]\]. Importantly, the extracellular matrix (ECM) that remains after the decellularization process maintains the delicate glomerular and tubular structures as well as the vascular tree of the kidney. Furthermore, the ECM is able to modulate the phenotype of seeded progenitor cells, which express renal developmental genes in response \[[@CR86], [@CR90], [@CR91]\]. In addition, immunogenicity is reduced since major immunogenicity antigens are lost after decellularization \[[@CR83]•\]. This raises the possibility that decellularised kidneys from other species could be used as a source of scaffold for transplantation, the advantage being that such kidneys would be in pristine condition, whereas human kidneys deemed unsuitable for transplantation could have structural damage. The pig is particularly attractive because the size and microarchitecture of pig and human kidneys are similar \[[@CR92]\].

Following decellularisation of the kidney scaffold, the next challenge is to repopulate with renal cells and endothelial cells. Most studies have focused on the rat kidney as a model to study the effects of re-cellularisation on cell distribution and function, using various cell combinations, including mouse ESCs \[[@CR86], [@CR93], [@CR94]\], human iPSC-derived endothelial cells with human renal cortical tubular epithelial cells \[[@CR95]\], rat aorta endothelial with rat epithelial tubular cells \[[@CR96]\] and human umbilical vascular endothelial cells with rat neonatal kidney cells \[[@CR2]••\]. Other groups have reported re-cellularisation of decellularised mouse, pig and rhesus monkey kidneys using human kidney cells, foetal rhesus monkey kidney cells or ESCs \[[@CR2]••, [@CR82], [@CR87], [@CR94], [@CR97]\]. Interestingly, ESCs seeded into the kidney scaffolds have been shown to populate the matrix with evidence of site-appropriate differentiation, indicating that the ECM of the decellularised kidneys can instruct the ESCs to differentiate into renal and vascular elements of the kidney \[[@CR86], [@CR93], [@CR94]\].

Research in this field is still ongoing, and currently, optimal re-cellularisation techniques are being developed. Three major challenges are being recognised: the requirement for an autologous cell type that can differentiate into both endothelial and specialised kidney cells, a strategy for achieving complete re-cellularisation and the application of a transrenal pressure gradient. Previous studies have explored the use of endothelial and renal progenitor cells from various sources \[[@CR2]••, [@CR95], [@CR96]\], but it is clear that iPSC-derived RPCs and endothelial cells present the best route forward due to the fact that they are autologous and RPCs can generate all cell types of the nephrons and collecting tubules.

In order to re-cellularise the kidney, Caralt and colleagues performed perfusion experiments separately by injecting either human iPSC-derived endothelial cells or an immortalised human renal cortical tubular epithelial cell line via the renal artery. While excellent vascular repopulation by the endothelial cells was observed, it was found that after 24 h, only 50 % of the renal tubules were re-cellularised by the kidney cells \[[@CR95]\]. Using a different approach involving perfusion of rat endothelial cells and tubule epithelial cells via the renal artery (antegrade) and ureter (retrograde), respectively, it was shown that the vascular network could be efficiently repopulated by the endothelial cells, which were able to survive and proliferate, while the tubular epithelial cells failed to populate the kidney scaffold sufficiently. This study also involved the use of a specifically designed bioreactor which allowed the application of a transrenal pressure gradient during the seeding procedure. It was found that the arterial pressure increased in the kidneys repopulated with endothelial cells, indicating functionality of the endothelial cells through changes in flow resistance \[[@CR96]\].

The most promising demonstration of re-populating decellularised kidneys has been reported by the Ott group who successfully managed to seed both human umbilical vascular endothelial cells and rat neonatal kidney cells into decellularised rat kidneys. They combined antegrade seeding of endothelial cells with retrograde seeding of the kidney cells under the application of a transrenal pressure gradient in a special bioreactor. The cells populated half of the glomeruli and nephron structures across the kidney scaffold and expressed tissue-specific markers. Furthermore, the repopulated kidneys were assessed for their functionality ex vivo and displayed some degree of filtration capacity, whereas the decellularised kidneys did not. Of note, when the re-cellularised kidneys were transplanted orthotopically into recipient rats, it was found that urine-like solution could be produced, albeit at lower levels than in native kidneys \[[@CR2]••\].

Taken together, while highly promising, these results demonstrate that further optimisation is needed to generate fully functional bioengineered kidneys using decellularised scaffolds. Specifically, one of the main challenges is to achieve the full repopulation of the decellularised kidney scaffold in an organotypic way, resulting in correct spatial distribution of appropriately differentiated renal and endothelial cells which physiologically interact to perform the filtration function of the kidney (Fig. [1](#Fig1){ref-type="fig"}). As discussed below, this could potentially be overcome by using a bioprinting approach that simultaneously prints the cells along with an appropriate synthetic scaffold, thereby circumventing the repopulation problem.

3D Bioprinting {#Sec10}
==============

Three-dimensional (3D) bioprinting is an emerging technology that facilitates the layer-by-layer precise positioning of biological materials, biochemicals and living cells, with spatial control of the placement of functional components \[[@CR98]\]. 3D printing technology offers alternative approaches to generating organotypic scaffolds for bioengineering of organs. A pioneering study by the group of Atala showed that 3D bioprinting could be used to generate a biodegradable scaffold of a human bladder. These bioengineered bladders were seeded with autologous urothelial and muscle cells and were transplanted into seven patients with non-functional bladders \[[@CR99]\]. 3D bioprinting of various other tissues, such as vessels and tracheal grafts, has also been achieved \[[@CR100], [@CR101]\]. However, it should be noted that the aforementioned tissues and organs are relatively simple structures, whereas the kidney is much more complex, containing approximately one million nephrons. For this reason, the possibility of engineering a 3D-bioprinted kidney is currently beyond our capabilities. However, with further advances in this technology, it could be possible to combine 3D printing of the kidney scaffold with autologous RPCs and endothelial cells in order to generate personalised kidneys for patients with ESRD (Fig. [1](#Fig1){ref-type="fig"}). Interestingly, Organovo Inc. has recently presented a 3D bioprinted model of 'kidney proximal tubular tissue'. The 3D tissue, which consisted of proximal tubule cells, renal interstitial cells and endothelial networks, could be maintained in culture for up to two weeks \[[@CR102]\].

Safety Issues {#Sec11}
=============

The main safety issues concerning bioengineered kidneys relate to the cell types used to repopulate the kidney, and the source of the renal scaffold.

Cell-Related Safety Issues {#Sec12}
==========================

As previously mentioned, iPSC-derived RPCs are most promising due to the fact that they can generate all cell types within the kidney \[[@CR63]••, [@CR64]••\]. However, pluripotent cells such as iPSCs pose particular risks due to their propensity to form teratomas, or even teratocarcinomas. It would therefore be very important to ensure that the RPC population used in the therapy did not contain any undifferentiated iPSCs. Before transplanting bioengineered kidneys into man, it would also be crucial to track their fate in preclinical models in order to assess whether they migrate to distant organs and tissues where they could potentially maldifferentiate or form tumours \[[@CR103]\]. Particular caution would be needed with immunosuppressed transplant patients, for it is known that immunosuppressant therapy significantly increases the risk of tumour formation \[[@CR104]\]. The use of autologous cells should hopefully obviate the need for immunosuppressants, though they might still be required if the source of scaffold was found to be immunogenic. Despite the concerns related to the use of pluripotent cell therapies, a number of clinical trials are in progress to assess their safety in the treatment of particular diseases, such as the use of ESC-derived retinal pigment epithelial cells in patients with age-related macular degeneration \[[@CR105]\]. To date, there have been no reports of recipients of ESC-based therapies developing tumours, which suggest that if sufficient care is taken to ensure that the administered population has a normal karyotype, has been scaled up under conditions of Good Manufacturing Practice, and is not contaminated with undifferentiated cells, the therapy is likely to be safe.

Scaffold-Related Safety Issues {#Sec13}
==============================

Decellularised scaffolds are unlikely to pose particular safety issues because they are composed of native ECM. It would be expected that the ECM would be degraded over time and replaced with new ECM derived from the cells used to repopulate the scaffold. A potential safety issue might arise if the rate of ECM degradation was faster than that of new ECM deposition, as this would be expected to affect the integrity of the scaffold. Of note, the patient who received a bioengineered airway generated from a decellularised scaffold remained well at 5 years follow-up \[[@CR80]\], suggesting that this could be a safe approach, at least for tissues and organs with simple structures. However, the number of clinical studies conducted to date are too few to confirm the safety and feasibility of this approach \[[@CR106]\]. Synthetic and/or bio-printed substrates would be expected to pose more safety issues than bioengineered organs comprising decellularised scaffolds simply because their composition would be different than that of native scaffolds. For this reason, it could be difficult to predict how they might interact with the host over the short or long term. A recent report indicating a high incidence of death (6 out of 8) in patients transplanted with synthetic tracheas \[[@CR107]\] demonstrates the need for this field to progress cautiously within a robust regulatory framework.

Conclusions {#Sec14}
===========

In the last few years, tremendous progress has been made towards the development of autologous cells for kidney bioengineering. The key advance has been the development of RPCs derived from pluripotent stem cells (i.e. ESCs and iPSCs) that can generate all cells of the nephron and collecting tubules and have the ability to self-organise in vitro to form renal organoids \[[@CR63]••, [@CR64]••\]. It is unlikely that these organoids will be useful as a therapy to directly treat patients with ESRD because based on previous studies with rudiment transplants \[[@CR72]\], they would probably not mature sufficiently and would not be connected with the host's urinary excretory system. Nevertheless, renal organoids present an excellent model system for understanding kidney development and disease and for drug screening programmes. In regard to therapy, instead of transplanting renal organoids, a more promising approach would be to use iPSC-derived RPCs and endothelial cells to recellularise kidney scaffolds derived either from human donor kidneys or pig kidneys. Much progress has been made towards this goal \[[@CR2]••\], but the key challenge that still needs to be overcome is that of repopulating the nephrons and ensuring that the cells differentiate and function appropriately according to their position along the renal tubule. 3D bioprinting could potentially solve this problem, but despite the significant and exciting advances that have been made, printing complex organs like the kidney will not be happening soon, as the technology requires a considerable amount of time to evolve.
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